Clinical characteristics and associated factors in antipsychotic-induced akathisia of Asian patients with schizophrenia

Chong, Siow‐Ann; Mythily,; Remington, Gary

doi:10.1016/s0920-9964(02)00156-1

Cited by 13 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is slightly higher than previously reported in predominantly Caucasian populations over 3-week treatment periods (aripiprazole vs. placebo); 11 vs. 2% (Keck et al 2003) and 18 vs. 5% (Sachs et al 2006). This observation is in contrast to previous research that has suggested a lower tendency to develop akathisia with antipsychotic treatment in Asian patients compared with Western populations (Chong et al 2003). Taken together with inherent limitations in comparing results between studies, it is unclear why reported rates of akathisia were higher in this study than previously reported with aripiprazole.…”

Section: Safety and Tolerabilitycontrasting

confidence: 80%

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study)

Kanba

Kawasaki

Ishigooka

et al. 2012

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

show abstract

Section: Safety and Tolerabilitycontrasting

confidence: 80%

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study)

Kanba

Kawasaki

Ishigooka

et al. 2012

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

show abstract

“…66,67 There is no clear evidence of risk associated with age, gender, or ethnic background. 56,68 Chronic or tardive akathisia may be associated with advanced age and female gender, just as is tardive dyskinesia. 21…”

Section: Risk Factors For Drug-induced Akathisiamentioning

confidence: 99%

“…Other risk factors may include higher dose or rapid dose increase, 63 traumatic brain injury, 64 , 65 cancer, 43 and possibly iron deficiency 66 , 67 . There is no clear evidence of risk associated with age, gender, or ethnic background 56 , 68 . Chronic or tardive akathisia may be associated with advanced age and female gender, just as is tardive dyskinesia 21 …”

Section: Risk Factors For Drug-induced Akathisiamentioning

confidence: 99%

The clinical challenges of akathisia

et al. 2015

View full text Add to dashboard Cite

Akathisia is one of the most vexing problems in neuropsychiatry. Although it is one of the most common side effects of antipsychotic medications, it is often difficult to describe by patients, and is difficult to diagnose and treat by practitioners. Akathisia is usually grouped with extrapyramidal movement disorders (ie, movement disorders that originate outside the pyramidal or corticospinal tracts and generally involve the basal ganglia). Yet, it can present as a purely subjective clinical complaint, without overt movement abnormalities. It has been subtyped into acute, subacute, chronic, tardive, withdrawal-related, and "pseudo" forms, although the distinction between many of these is unclear. It is therefore not surprising that akathisia is generally either underdiagnosed or misdiagnosed, which is a serious problem because it can lead to such adverse outcomes as poor adherence to medications, exacerbation of psychiatric symptoms, and, in some cases, aggression, violence, and suicide. In this article, we will attempt to address some of the confusion surrounding the condition, its relationship to other disorders, and differential diagnosis, as well as treatment alternatives.

show abstract

“…A possible reason for the superior effectiveness of aripiprazole, especially in Asian populations, may be related to ethnic differences in pharmacological properties. Although there is no significant difference with regard to ethnicity in the treatment response to aripiprazole 30 , some evidence has suggested more favorable safety profiles in Asian patients than in Caucasian patients 19,31 . Since effectiveness takes into account the parameters of efficacy and safety/tolerability, an inter-ethnic difference in the vulnerability for the development of side effects may lead to differences in the effectiveness of aripiprazole.…”

Section: Discussionmentioning

confidence: 99%

“…The issue of ethno-psychopharmacology, defined as dramatic cross-ethnic variations in dosing and side effects in response to psychotropics, has received considerable critical attention 15 . Previous studies have investigated the influence of ethnicity on the metabolism 16 , pharmacogenetics 17 , dosing 18 , and side effects of antipsychotic medications 19 in addition to medication adherence 20 . Ethnic differences in these factors may eventually lead to differences in antipsychotic effectiveness or overall treatment response 9,21,22 .…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital

Lee

Kim

et al. 2020

npj Schizophr

View full text Add to dashboard Cite

Extensive research has been carried out on the comparative effectiveness of antipsychotic medications. Most studies, however, have been performed in Western countries. The purpose of this study was to compare the effectiveness, indicated by time to any-cause discontinuation, of antipsychotic drugs in a large number of patients with schizophrenia in South Korea. We identified 1458 patients with schizophrenia or schizophreniform disorder who were treated with antipsychotic medications using a clinical data warehouse at the Seoul National University Hospital between March 2005 and February 2014. Kaplan–Meier survival analyses were used to estimate the time to discontinuation of antipsychotic drugs. We compared the survival curves of different antipsychotics using log-rank tests. Overall, the median time to discontinuation for any cause was 133 days (95% CI, 126–147). The longest time to discontinuation was observed for clozapine, followed by aripiprazole, paliperidone, olanzapine, amisulpride, risperidone, quetiapine, ziprasidone, and haloperidol. Specifically, clozapine was significantly different from all other antipsychotic drugs (all p < 0.001). Aripiprazole also had a significantly longer time to discontinuation than amisulpride (p = 0.001), risperidone (p < 0.001), quetiapine (p < 0.001), ziprasidone (p < 0.001), and haloperidol (p < 0.001). In Asian patients with schizophrenia, clozapine was the most effective antipsychotic in terms of time to discontinuation, followed by aripiprazole. This study extends the findings of previous effectiveness studies from Western populations and suggests the need to develop guidelines for the pharmacotherapy of schizophrenia tailored to Asian individuals.

show abstract

Clinical characteristics and associated factors in antipsychotic-induced akathisia of Asian patients with schizophrenia

Cited by 13 publications

References 22 publications

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study)

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole for the treatment of acute manic or mixed episodes in Asian patients with bipolar I disorder (the AMAZE study)

The clinical challenges of akathisia

Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital

Contact Info

Product

Resources

About